Intravenous Lidocaine does not Reduce Emergence Agitation or Pain after Sevoflurane Anesthesia in Children

Department of Anesthesiology and Pain Medicine, School of Medicine, Keimyung University, Daegu, Korea

Young Ho Jang, M.D, and Soo Ryung Oh, M.D.

Background: Sevoflurane has a higher incidence of emergence agitation (EA) in children. We examined the effect of IV lidocaine doing the incidence of EA and the severity of postoperative pain in children who received sevoflurane anesthesia.

Methods: Eighty five children aged 2-7 years undergoing sevoflurane anesthesia were studied. Patients were randomly assigned to one of the two groups: Group C (n = 42) wherein subjects received saline solution, and Group L (n = 43) where they received 1.5 mg/kg of IV lidocaine 5 minutes before emergence from anesthesia. The recovery time, EA score, CHEOPS score and modified Aldrete postanesthesia score were repeatedly measured at the postanesthesia care unit (PACU).

Results: The time until first cough was significantly longer in group L. The EA score and CHEOPS score were not significantly different between the two groups. There was no significant difference in the use of additional analgesics or sedatives for treatment of severe EA or severe pain.

Conclusions: After sevoflurane anesthesia, 1.5 mg/kg of IV lidocaine 5 minutes before extubation did not reduce the incidence of EA and the severity of postoperative pain. The time to discharge from the PACU was similar to that with placebo. (Korean J Anesthesiol 2005; 49: S 14 – 9)

Key Words: agitation, emergence, lidocaine, pain, pediatrics, sevoflurane.

INTRODUCTION

Sevoflurane has been associated with a high incidence of emergence agitation (EA) in children. The proposed causes of EA following sevoflurane anesthesia include rapid emergence, variable neurological activity, and increased pain sensation. A variety of pharmacological strategies, such as opioids (fentanyl or nalbuphine), ketamine, α2-agonists (clonidine or dexmedetomidine), midazolam or regional analgesia have been tried to reduce the incidence and severity of EA. Opioids are the most frequently used agents in this context largely due to their consistent and reliable results in the therapy for EA. However, the routine use of fentanyl to prevent EA is still questionable because of the increase in postoperative nausea and vomiting (PONV) in up to 75% cases and the associated delay in recovery. Nalbuphine, an agonist-antagonist opioid, may be an useful adjuvant to treat EA in children, but since it acts as antagonist at the mu opioid receptor site, it can potentially reverse the analgesia obtained by the administration of a mu opioid agonist. Orally or intravenously administered ketamine reduced the incidence of EA in children. But results in nystagmus as well as an increased need for oxygen supplementation following extubation. Midazolam and other sedatives significantly prolong the duration of emergence when used to reduce the incidence of EA. Therefore, they can be safely used only after the pain has been adequately controlled. Emergence from anesthesia and discharge time have been shown to be prolonged after premedication with midazolam in children receiving sevoflurane anesthesia.

Intravenous (IV) lidocaine suppresses neural excitability and reduces the neural response to postoperative pain by inhibition of nerve conduction. It suppresses central sensitization and reduces postoperative pain in the clinical setting. However, the beneficial effect of IV lidocaine on acute pain is still debatable. Despite these observations, prophylactic IV lidocaine given pre-extubation is well known to attenuate patient response to tracheal extubation.
had a significant elevation of sedation score in the early postoperative period after tonsillectomy and adenoidecotomy.\textsuperscript{20}

The purpose of the present study was to investigate the effect of IV lidocaine on the incidence of EA and postoperative pain following sevoflurane anesthesia in children.

**MATERIALS AND METHODS**

This study was a randomized, double blind, single-dose trial. After obtaining approval from the Clinical Investigation Committee and written informed parental consent, 2-7 year-old pediatric patients scheduled to have superficial lower abdominal and genital surgery were enrolled. All patients were ASA physical status I or II and were scheduled to receive general anesthesia with sevoflurane. Children who had an experience of previous general anesthetic and children with central nervous system, hepatic or renal dysfunction, sleep apnea, developmental delay, or preceding psychological or psychiatric disorders were excluded from the study. Patients fasted for 4-6 hours prior to surgery as a part of the standard pre-anesthetic protocol in our institute. No sedative premedication was administered prior to the induction of anesthesia.

One of parents stayed with the child in the operating room (OR) during the induction of anesthesia. Standard monitoring was performed throughout the stay in the OR, including electrocardiography (ECG), pulse oximetry (SpO₂), noninvasive blood pressure (NIBP), and temperature. End-tidal concentrations of carbon dioxide (ETCO₂) and sevoflurane were measured continuously using infrared anesthetic gas analyzer (Capnomac, Datex-Ohmeda, Finland). Ondansetron was administered at 0.1 mg/kg (maximum 4 mg) to reduce the incidence of PONV. Anesthesia was administered by the same anesthesiologist for all the procedures included this study. All investigators evaluating the children during the intra- and postoperative period were blinded to each group.

Pre-induction distress of the patients was measured by the participating anesthesiologist and rated on a four-point score (1 = calm and cooperative, 2 = mildly anxious but consolable, 3 = tearful and inconsolable, 4 = totally out of control) proposed by Keaney et al.\textsuperscript{21} All patients received 100% oxygen prior to anesthetic induction using an alternative supplemental oxygen source and a face mask. Following preoxygenation, patients took tidal or vital capacity breath using a face mask with primed circuit, with 8 vol% dialzed sevoflurane (Vaporizer 2000, Drager, Wisconsin, USA) in a mixture of 75% nitrous oxide in oxygen at 4 L/min fresh gas flow. Cricoid pressure was applied following loss of consciousness and eyelash reflex. Assisted ventilation with a face mask was gradually switched to standard controlled ventilation. IV access was established and an infusion of D\textsubscript{5}\textsubscript{5}W\textsubscript{0.4}NS was started, as per our institute’s standard practice. Nitrous oxide was discontinued 1 minute following satisfactory inhalation induction and the vaporizer was set to 3% sevoflurane in 100% oxygen at 4 L/min for endotracheal intubation. The sevoflurane concentration was adjusted according to patient’s vital signs with nitrous oxide 50% in oxygen. Ventilation was assisted to attain ETCO\textsubscript{2} between 35-40 mmHg during the procedure. No analgesics or local anesthetics other than study drug were administered during surgery, except 0.1 mg/kg of IV ondansetron as part of anesthetic regimen.

Patients were randomly assigned to one of the two groups (Group C; Control vs. Group L; IV Lidocaine). To protect the double blind design of the study, all study drugs and placebos were prepared and labeled with only the patients’ name and hospital number by one OR nurse who did not participate in the process of evaluation of study groups. Patients in Group L received 1.5 mg/kg IV lidocaine over 30-45 seconds 5 minutes before discontinuation of their anesthetic by the blinded anesthesiologist. Group C patients received an equal volume of IV saline.

At the conclusion of the operative procedure, sevoflurane and nitrous oxide were simultaneously discontinued. Spontaneous respiration was permitted following the return of the cough reflex. Patients were extubated and transferred to the postanesthesia care unit (PACU) once they demonstrated a regular respiratory pattern, facial grimacing, gag reflex and purposeful movements. The time until first cough, facial grimacing, eye opening and time to extubation following discontinuation of sevoflurane and nitrous oxide were documented.

One trained anesthesiologist, blinded to patient group assignment, was present upon admission to the PACU. The ECG, NIBP and SpO₂ monitoring were measured throughout the stay in PACU. A parent was allowed to be at the child’s bedside immediately upon admission to the PACU. Adverse events including hypotension, seizure, deep sedation, arrhythmia, and PONV were recorded during the recovery period.

Postoperative pain was assessed using the CHEOPS (Children’s Hospital of Eastern Ontario Pain Scale) scores based on crying, facial expression, verbal statements, position of torso, touching of the wound, and movement of legs.\textsuperscript{22} EA score was evaluated by using five-point scores (1 = obtunded patient with no response to stimulation, 2 = asleep but responsive to movement or stimulation, S 15
3 = awake and appropriately responsive, 4 = crying and difficult to console, 5 = wild thrashing behavior that requires restraint) by Cravero et al. A EA score ≥ 4 or CHEOPS score ≥ 9 despite all calming efforts by the child’s parents or guardians and nursing personnel were considered as severe EA or severe pain, respectively. IV ketolarac tromethamine (0.5 mg/kg) was administered in such situations. Fentanyl (1µg/kg) was administered if severe EA or severe pain persisted even after IV ketorolac tromethamine administration.

A score of ≥ 8 on the modified Aldrete postanesthesia score was used as the criterion for transferring subjects from PACU to ward. The EA score, CHEOPS score and modified Aldrete postanesthesia score were serially documented for 20 minutes with the 5 minute interval upon arrival in the PACU. Then the children were allowed to transfer from PACU to the ward after confirmation of the modified Aldrete postanesthesia score ≥ 8 points. The time to modified Aldrete postanesthesia score ≥ 8 and the time to discharge from the PACU were recorded.

Analyses were performed using the SPSS statistical Package program version 11.0 (SPSS for windows, SPSS Inc., Chicago, IL, USA). Data are expressed as means ± SD. Sample size calculation was performed by considering the 30% incidence of severe EA based on the report by Beskow and Westrin. With power of 80% and type 1 error of 5%, we calculated that 39 subjects were required per group. Data were analysed using Student’s t-test and Kruskal-Wallis tests when comparing the demographic data. Nonparametric data including sex, EA score, CHEOPS score, and modified Aldrete score were compared by using χ² analysis and Fisher’s exact test. P-values < 0.05 were considered statistically significant.

### Table 1. Demographic Data and Preoperative Distress Scale

<table>
<thead>
<tr>
<th></th>
<th>Group C (n = 42)</th>
<th>Group L (n = 43)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr)</td>
<td>4.6 ± 2.0</td>
<td>4.3 ± 1.7</td>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>21/21</td>
<td>23/20</td>
</tr>
<tr>
<td>Body weight (kg)</td>
<td>19.3 ± 7.0</td>
<td>18.1 ± 4.4</td>
</tr>
<tr>
<td>Duration of anesthesia (min)</td>
<td>61.7 ± 25.3</td>
<td>62.4 ± 26.1</td>
</tr>
<tr>
<td>Preoperative distress scale</td>
<td>1.8 ± 0.9</td>
<td>1.9 ± 1.0</td>
</tr>
</tbody>
</table>

Values are mean ± SD. Group C: control, Group L: 1.5 mg/kg of IV lidocaine 5 minutes before extubation. Preoperative distress scale: 1 = calm and cooperative, 2 = mildly anxious but consolable, 3 = tearful and inconstable, 4 = totally out of control. No significant difference between two groups.

### Results

The groups were similar in respect to age, gender, weight and anesthetic duration (Table 1). Preoperative distress scores in children were 1.8 ± 0.9 in group C and 1.9 ± 1.0 in group L, respectively (P > 0.05). None of the patients in either group experienced any episodes of hypoxia, hypotension, seizure, deep sedation, arrhythmia or PONV requiring treatment during their postoperative stay in the PACU.

There were no significant differences during recovery with respect to the time to facial grimacing, eye opening and extubation after discontinuation of sevoflurane and nitrous oxide between the two groups, although the time until first cough was significantly longer in group L (Table 2).

The five-point EA score and CHEOPS score on arrival at PACU were not significantly different between the two groups. There was no significant difference in the time to modified Aldrete

### Table 2. Emergence Characteristics

<table>
<thead>
<tr>
<th></th>
<th>Group C (n = 42)</th>
<th>Group L (n = 43)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time to first cough (min)</td>
<td>6.6 ± 3.8</td>
<td>8.9 ± 6.3#</td>
</tr>
<tr>
<td>Time to facial grimacing (min)</td>
<td>9.5 ± 6.8</td>
<td>10.1 ± 8.4</td>
</tr>
<tr>
<td>Time to eye opening (min)</td>
<td>16.4 ± 9.8</td>
<td>19.8 ± 10.8</td>
</tr>
<tr>
<td>Time to extubation (min)</td>
<td>7.7 ± 3.8</td>
<td>8.7 ± 3.5</td>
</tr>
</tbody>
</table>

Values are mean ± SD. Group C: control, Group L: 1.5 mg/kg of IV lidocaine 5 minutes before extubation. #P < 0.05 vs. group C.

### Table 3. Progress during Stay at Postanesthesia Care Unit

<table>
<thead>
<tr>
<th></th>
<th>Group C (n = 42)</th>
<th>Group L (n = 43)</th>
</tr>
</thead>
<tbody>
<tr>
<td>EA score on arrival at PACU</td>
<td>2.6 ± 1.3</td>
<td>2.3 ± 1.5</td>
</tr>
<tr>
<td>CHEOPS score on arrival at PACU</td>
<td>7.7 ± 2.2</td>
<td>7.4 ± 2.0</td>
</tr>
<tr>
<td>Time to modified Aldrete score ≥ 8 (min)</td>
<td>6.2 ± 8.0</td>
<td>8.1 ± 10.1</td>
</tr>
<tr>
<td>Time to discharge from PACU (min)</td>
<td>21.4 ± 10.0</td>
<td>21.5 ± 8.9</td>
</tr>
</tbody>
</table>

Values are mean ± SD. Group C: control, Group L: 1.5 mg/kg of IV lidocaine 5 minutes before extubation. EA: emergence agitation, PACU: postanesthesia care unit, CHEOPS: Children’s Hospital of Eastern Ontario Pain Scale. Modified Aldrete score and agitation score: see the text.
postanesthesia score $\geq 8$ and the time to discharge from the PACU between the two groups (Table 3).

Ten children (23.8%) in group C and 11 (25.6%) in group L experienced severe EA (five-point EA score $\geq 4$) (Fig. 1). Fifteen children (35.7%) of group C and 12 (27.9%) of group L experienced severe pain (CHEOPS score $\geq 9$). There were no significant differences in the incidence of severe EA or severe pain between the two groups.

Sixteen (38.1%) patients in group C and 15 (34.9%) patients in group L received IV ketorolac tromethamine for severe EA and/or severe pain ($P > 0.05$). Eight (19.0%) patients in group C and 8 (18.6%) patients in group L received additional IV fentanyl because the EA and/or CHEOPS scores were not reduced to below moderate following the administration of IV ketorolac tromethamine (Fig. 2).

**DISCUSSION**

Postoperative IV lidocaine is known to reduce the incidence of postoperative cough and improve postoperative outcome. A thorough literature search did not reveal any previous investigations looking at the effect of IV lidocaine on EA following sevoflurane anesthesia in children. The present study was designed to investigate the effects of single-bolus placebo and IV lidocaine on the incidence and severity of EA and recovery from anesthesia.

The reported incidence of EA in children after sevoflurane anesthesia varies from 10 to 80%. Various factors, such as opioid administration, premedication, postoperative pain, patient’s age, scoring system or preoperative anxiety are associated with the incidence of EA after anesthesia. The incidences of severe EA in our study were 23.8% in control group and 25.6% in lidocaine group, respectively, which are similar to an earlier report by Beskow and Westrin. Unexpectedly, the administration of IV lidocaine 1.5 mg/kg 5 minutes before discontinuation of sevoflurane did not reduce the incidence of EA in children in this study protocol.

Repeated assessments of EA following anesthetic recovery are essential to define the incidence and duration of EA. We limited our observations to EA and CHEOPS scores for only 20 min with 5 minute interval upon arrival in the PACU due to a busy PACU circumstances and a rapid turnover surgical setting. However, the highest incidence of EA occurs within the first 10 minutes and progressively decreases with increasing time following anesthesia. Therefore, we think that our observational period of 20 minutes may be sufficient to reflect the total incidence of EA and pain at PACU.

Sevoflurane and desflurane are volatile agents with low blood and tissue solubilities. Thus, they are associated with a high incidence of EA in children. There are numerous adverse effects of EA, including a risk of self-injury, bleeding, and inadvertent removal of drains and intravenous catheters. EA may complicate postanesthetic care and delay discharge from PACU. Consequently, children who experience EA generally
require the administration of additional analgesics or sedatives, as well as additional nursing care. EA may be the result of a rapid washout of sevoflurane, thereby resulting in sub-anesthetic concentrations that do not provide analgesia. Adequate postoperative analgesia appears to be necessary to minimize the incidence of excitatory effects. This was demonstrated in an analysis that found the incidence of EA among subjects receiving sevoflurane to be significantly higher in patients undergoing inguinal hernia repair when they did not receive caudal anesthesia for adequate pain relief. Differentiating between EA and pain in children during immediate postoperative period is extremely difficult and may sometimes be impossible. Most of our patients who received additional analgesics (IV ketorolac tromethamine with or without additional fentanyl) had both severe EA and severe pain. There were no significant differences in the use of IV ketorolac tromethamine and fentanyl with or without administration of IV lidocaine. In other words, 1.5 mg of IV lidocaine did not reduce the incidence of severe EA and pain following emergence from sevoflurane anesthesia.

We did not measure lidocaine blood concentrations in this study. Lidocaine blood levels peak at the first minute after an IV bolus (28). Koc et al. demonstrated that IV lidocaine 1 mg/kg 5 minutes prior to extubation had a higher sedation score at five minutes postoperatively. This was the reason for administration of IV lidocaine 5 minutes before emergence from anesthesia in this study.

IV lidocaine acts as a central nervous system depressant and has a sedative effect. Therefore, it increases the depth of general anesthesia. In our study, the time to modified Aldrete score, CHEOPS score and the time to discharge from the PACU were not significantly different between the two groups. As a result, we did not observe any sedative effect in our patients following 1.5 mg/kg IV lidocaine after sevoflurane anesthesia.

In conclusion, 1.5 mg of IV lidocaine 5 minutes before extubation at the end of surgery prolonged the time until first cough after sevoflurane anesthesia in children. The incidence of EA, severity of postoperative pain and the time to discharge from the PACU were not significantly different when compared to the placebo. Further studies on EA are indicated to determine if this treatment is warranted.

REFERENCES


